4dmedical Ltd. · ASX:4DX
4dmedical — Investor Presentation (March 2021)
31 slides from 4dmedical's investor presentation, Mar 4, 2021
Slide 1: Award of MRFF Frontier Grant & Capital Raising Presentation
Award of MRFF Frontier Grant & Capital Raising Presentation 4 March 2021 ASX: 4DX 4DMedical Limited | ACN 161 684 831 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (Group) and their activit
Slide 3: Important Notice and Disclaimer
Important Notice and Disclaimer Hong Kong WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong
Slide 4: Important Notice and Disclaimer
Important Notice and Disclaimer In the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 200
Slide 5: Executive summary
Executive summary • Founded in 2012, 4DMedical is a Melbourne-based healthcare technology company focused on commercialising its patented lung imaging platform – XV Technology ™ • 4DMedical is currently progressing the global rollout of its XV Lung Ventilation Analysis Software (XV LVAS™), which has
Slide 6: Agenda
Agenda i. Overview of ALHI ii. XVD Scanners iii. Capital Raising Details iv. Appendix 6 | MRFF Grant & Capital Raising NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 7: Overview of ALHI
Overview of ALHI A new frontier for respiratory diagnostics 7 | MRFF Grant & Capital Raising NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 8: ALHI & MRFF Frontier funding
Overview of ALHI ALHI & MRFF Frontier funding ALHI has been awarded $28.9m of funding over the next five years under the MRFF Frontier initiative • Australian Lung Health Initiative Pty Ltd (ALHI) is a joint venture between 4DMedical, the University of Adelaide and the South Australian Health and Me
Slide 9: ALHI structure & partners
Overview of ALHI ALHI structure & partners • ALHI is a consortium incorporated and led by 4DMedical with support from global leaders in the medical field • 4DMedical has been granted the right to commercialise XVD Scanners and will receive 100% of revenue from XVD Scanner hardware, SaaS sales genera
Slide 10: Strong support from key opinion leaders
Overview of ALHI Strong support from key opinion leaders “[This program] will provide, “…having recently seen the … “The proposed research partnership “[This program] has the ability for the first time, rapid developments during Stage offers a unique opportunity to to change the lives of people deta
Slide 11: XVD Scanners
XVD Scanners The first dedicated lung function scanner: high-throughput, very low dose and greater scanning flexibility 11 | MRFF Grant & Capital Raising NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 12: Introduction to XVD Scanners
XVD Scanners Gen 1 XVD Scanner concept developed Introduction to XVD Scanners under MRFF Frontier Stage One • ALHI will deliver two generations of dedicated lung function scanners (Gen 1 & Gen 2) developed without the limitations of existing infrastructure: • Higher detail and greater accuracy than
Slide 13: Generation one & two development
XVD Scanners Generation one & two development ALHI will develop two generations of XVD Scanners that will each deliver reduced risk and increased reward Generation One Generation Two Gen 1 commence Gen 2 commence commercialisation commercialisation expected in 2023 expected in 2025 Gen 1 features Ge
Slide 14: Primary customers & use cases
XVD Scanners Primary customers & use cases 4DMedical is responsible for global sales and marketing of XVD Scanners in the field of lung health • 4DMedical will receive 100% of revenue from XVD Scanner hardware sales, XV LVAS software sales, and associated service revenue • 4DMedical has developed an
Slide 15: Multi-dimensional healthcare impact
XVD Scanners Multi-dimensional healthcare impact • Earlier diagnosis Diagnosis & Patient • Lung function assessment for children treatment accessibility & • Richer and more sensitive data • Flexible: standing, seated, ICU bed experience • Data-driven personalised treatments • Improved physical acces
Slide 16: 4DMedical licensing & revenue model
XVD Scanners 4DMedical licensing & revenue model • 4DMedical will receive 100% of revenue generated from XVD 4DMedical Indicative Return on first 10 XVD Scanners1 Scanners and has allowed for a ~2% royalty of net hardware sales once commercialised Gen 1 Gen 2 • 4DMedical has been granted the exclusi
Slide 17: Research & regulatory pathway
XVD Scanners Research & regulatory pathway Project funding Key opinion leaders (KOLs) support • MRFF funding will cover the majority of R&D and the first regulatory clearance • Prototype XVD Scanners will be allocated to high profile medical institutions for XVD Scanners – e.g. FDA 510(k) globally w
Slide 18: Manufacturing & components
XVD Scanners Manufacturing & components • 4DMedical is currently renting a ~1,700m2 facility near its Melbourne headquarters where it will conduct R&D, manufacturing and testing of XVD Scanners • The facility will have the capacity to support 4DMedical’s existing XV Technology activities, as well as
Slide 19: Capital Raising Details
Capital Raising Details 19 | MRFF Grant & Capital Raising NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 20: Indicative offer details
Capital Raising Indicative offer details • Placement to institutions, sophisticated and professional investors to raise approximately A$40.0 million via the issue of Placement approximately 25.8 million shares • Placement under the Company’s existing 15% Placement capacity under ASX Listing Rule 7.1
Slide 21: Timetable
Capital Raising Timetable Trading halt following award of MRFF grant Friday, 26 February 2021 Company enters suspension for capital raising Tuesday 2, March 2021 Transaction announced & Company resumes trading Thursday, 4 March 2021 Settlement of new Placement shares Wednesday, 10 March 2021 Allotme
Slide 22: Appendix
Appendix 22 | MRFF Grant & Capital Raising NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 23: Global lung diagnostics market opportunity
Appendix Global lung diagnostics market opportunity 4DMedical considers its market opportunity to be supplementing or replacing existing respiratory diagnostic modalities. In 2019, more than US$31 billion was spent on respiratory diagnostics across more than 377 million procedures globally. Country
Slide 24: The current modality gap
Appendix The current modality gap Current best practice respiratory diagnostics are decades out of date, not fit for purpose and are ripe for displacement. While each provides important insights, they often detect lung disease too late for effective treatment. Their limitations leave both doctors an
Slide 25: XV Technology combines the best features of existing modalities
Appendix XV Technology™ combines the best features of existing modalities 1) Functional insight of spirometry at a regional level; 2) comparable radiation dose to X-ray; and 3) high-detail resolution of a CT scan Healthy Lung Diseased Lung Subtle defect Uniform ventilation Compensation Defect 25 | M
Slide 26: Corporate snapshot
Appendix Corporate snapshot Capital structure Senior management team Ticker 4DX Andreas Fouras Group Managing Director & CEO IPO offer price $0.73 Heath Lee Chief Financial Officer Share price (25 February 2021) $1.73 Craige Pendleton-Browne Chief Information Officer Shares on issue (m) 264.76 Paul
Slide 27: Risks
Appendix Risks Key Risks The Directors consider that, on receipt of funds from the placement and SPP, 4DMedical will have sufficient working capital to carry out its objectives. However, financial resources are limited and there is a risk that 4DMedical may never achieve profitability. 4DMedical may
Slide 28: Risks
Appendix Risks Key Risks The successful operation of 4DMedical in part relies on 4DMedical's ability to retain its existing key management personnel who have intimate knowledge of the business and its Key personnel risk products. The loss of any key members of management or the inability to attract
Slide 29: Risks
Appendix Risks Key Risks 4DMedical's business may not There is a risk that 4DMedical may fail to achieve commercialisation and distribution goals. 4DMedical technology needs to find acceptance in a competitive market. Market achieve its intended goals acceptance depends on numerous factors (includin
Slide 30: Contacts
Contacts Corporate Investor Relations Media Charlene Stahr Simon Hinsley Matthew Wright Company Secretary +61 401 809 653 +61 451 896 420 companysecretary@4dmedical.com shinsley@4dmedical.com matt@nwrcommunications.com.au For more information please visit www.4DMedical.com 30 | MRFF Grant & Capital
Slide 31: MRFF Grant & Capital Raising
31 | MRFF Grant & Capital Raising